Anaplastic lymphoma kinase (ALK) alterations (activating mutations, amplifications, and
fusions/rearrangements) occur in~ 3.3% of cancers. ALK fusions/rearrangements are …

The current approaches for cancer drug development lag behind an accelerated need in the
field for a fast and efficient method for evaluating drugs in the personalized medicine era. In …

Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-
clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …

The large diversity of central nervous system (CNS) tumor types in children and adolescents
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …

Anaplastic lymphoma kinase (ALK) is a member of the insulin receptor protein-tyrosine
kinase superfamily and was first discovered in anaplastic large-cell lymphoma (ALCL). ALK …

Abstract Purpose of Review Molecular profiling enables the evaluation of genetic alterations
for the diagnosis and classification of gliomas and the selection of appropriate therapies …

Advances in molecular profiling have led to improved understanding of glioma
heterogeneity. Results have been used to inform diagnostic classification and targeted …

The prognosis of glioma is poor as its pathogenesis and mechanisms underlying cisplatin
chemoresistance remain unclear. Nucleosome assembly protein 1 like 1 (NAP1L1) is …

Background High-grade gliomas (HGG) in young children pose a challenge due to favorable
but unpredictable outcomes. While retrospective studies broadened our understanding of …

Gliomas harboring oncogenic ROS1 alterations are uncommon and primarily described in
infants. Our goal was to characterize the clinicopathological features and molecular …